Remodelamento do fígado, pâncreas e tecido adiposo em modelo experimental de síndrome metabólica tratado com telmisartana, sitagliptina e metformina / Hepatic, pancreatic and adipose tissue remodeling in an experimental model of metabolic syndrome treated with telmisartan, sitagliptin and metformin
AUTOR(ES)
Vanessa de Souza Mello
FONTE
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia
DATA DE PUBLICAÇÃO
16/06/2010
RESUMO
Pharmacological intervention can minimize or even reverse adverse remodeling due to metabolic syndrome. This work sought to evaluate the effects of monotherapies and combinations of drugs on insulin sensitivity, adipose tissue morphology, pancreatic and hepatic remodelling in C57BL/6 mice fed a high-fat diet. Male C57BL/6 mice were fed a very high-fat diet (HF, 60% lipids) or standard chow (SC, 10% lipids) over 10 weeks, after which drug treatments began: HF-T (HF + Telmisartan, 5.2mg/Kg/day), HF-S (HF + Sitagliptin, 1.08g/Kg/day), HF-M (HF + Metformin, 310.0mg/Kg/day) and the drug combinations HF-TM, HF-TS and HF-SM. Treated groups also had free access to HF diet and treatments lasted 6 weeks. Morphometry, stereological tools, immunostaining, ELISA, Western blotting and electron microscopy were used. The HF diet yielded an overweight phenotype, oral glucose intolerance, hyperinsulinemia, hypertrophied islets and adipocytes, stage 2 steatosis (<33%) and reduced liver PPAR-alpha and GLUT-2, concomitant with enhanced SREBP-1 expression, in the HF group (P<0.0001). Conversely, all drug treatments resulted in significant weight loss, reversed insulin resistance, islet and adipocyte hypertrophy and alleviated hepatic steatosis. Only HF-T and HF-TS presented body weights similar to SC mice at the end of the experiment and the latter treatment reversed hepatic steatosis. Increased PPAR-alpha immunostaining parallel to higher GLUT-2 and reduced SREBP-1 expression explain the favourable hepatic outcomes. Restoration of adipocyte size was consistent with higher adiponectin levels and lower TNF-alpha levels (P<0.0001) in treated groups. In conclusion, all treatments were effective in controlling metabolic syndrome. The best results were achieved using Telmisartan and Sitagliptin as monotherapies or as a dual treatment, combining partial PPAR-gamma agonism and PPAR-alpha activation in the liver with extended incretin action
ASSUNTO(S)
doença não alcoólica do fígado gorduroso doença não alcoólica do pâncreas gorduroso obesidade telmisartana incretinas dieta hiperlipídica morfologia non alcoholic fatty liver disease non alcoholic fatty pancreas disease obesity telmisartan incretins high-fat diets
ACESSO AO ARTIGO
http://www.bdtd.uerj.br/tde_busca/arquivo.php?codArquivo=3847Documentos Relacionados
- Dieta hiperlipídica materna e pós-natal promove remodelamento adverso do fígado, pâncreas e tecido adiposo na prole
- Advances in Hepatic, Biliary and Pancreatic Surgery
- Tecido adiposo na encruzilhada no desenvolvimento da síndrome metabólica, inflamação e aterosclerose
- Diminuição da produção de leptina pelo tecido adiposo na obesidade associada à síndrome metabólica severa
- Eficácia da sitagliptina no controle glicêmico e na função cardiovascular de pacientes portadores de diabetes mellitus tipo 2 tratados com metformina e glibenclamida